**Core Concept**
Bedaquiline is a diarylquinoline antibiotic that targets the ATP synthase of Mycobacterium tuberculosis, a crucial enzyme for the bacterium's energy production. This action inhibits the growth of M. tuberculosis, making it an effective treatment for multidrug-resistant tuberculosis (MDR-TB).

**Why the Correct Answer is Right**
Bedaquiline works by binding to the proton channel of the ATP synthase, thereby reducing the energy available for the bacterium to multiply. This mechanism of action is distinct from other antibiotics that target different steps in the bacterial cell's metabolism. The unique action of bedaquiline has led to its approval for the treatment of MDR-TB, particularly in combination with other anti-tuberculosis medications.

**Why Each Wrong Option is Incorrect**
**Option A:** This statement is true as bedaquiline is indeed used in the treatment of MDR-TB.
**Option B:** This statement is true as bedaquiline has been shown to be effective in reducing the bacterial load in patients with MDR-TB.
**Option C:** This statement is false as bedaquiline is not an antifolate drug, which is a different class of antibiotics used to treat infections.

**Clinical Pearl / High-Yield Fact**
It's essential to remember that bedaquiline is a last-line treatment for MDR-TB and should be used in combination with other anti-tuberculosis medications to minimize the risk of developing resistance. The use of bedaquiline requires careful monitoring of the patient's liver function due to the potential risk of hepatotoxicity.

**Correct Answer: C. Bedaquiline is not an antifolate drug.**